Insights
Search Results
Client Highlights
4.14.26
Firm Advises Getlabs on Acquisition by Function
On April 8, 2026, Function Health announced it has acquired Getlabs, a leading mobile healthcare platform that brings licensed specialists directly to one's location. The acquisition allows for the continuation of Getlab’s nationwide network of providers, health systems, and partners, while advancing Function's broader commitment to making healthcare more accessible by building experiences around member needs. Wilson Sonsini Goodrich & Rosati advised Getlabs on the transaction.
Client Highlights
2.10.26
Firm Advises IVP as Lead Investor in Solace Health’s $130 Million Series C
On February 10, 2026, Solace Health announced a $130 million Series C funding round led by IVP, accelerating the company’s mission to make advocacy a standard part of care for every patient in the United States. The Series C values Solace at over $1 billion and reflects growing consensus that healthcare advocacy is no longer optional as costs rise and systems fracture. Wilson Sonsini Goodrich & Rosati advised IVP on the transaction.
The round also included participation from existing investors Menlo Ventures, SignalFire, Torch Capital, Inspired Capital, and RiverPark Ventures. With this funding, Solace will significantly expand its national network of more than 2,000 experienced advocates serving Medicare and Medicare Advantage members, while accelerating investment in its platform and clinical research. The company will also deepen partnerships with payers and providers to embed advocacy earlier in the care journey where outcomes are most at risk.
The Wilson Sonsini team that advised IVP on the transaction included Becki DeGraw, Madeleine Vella, Andrea Linna, Nawa Lodin, Chris Paniewski, Isabel Annino, and Daniel Chen.
For more information, please see Solace Health’s news release. Additional coverage is available on Fierce Healthcare and MedCity News.
The round also included participation from existing investors Menlo Ventures, SignalFire, Torch Capital, Inspired Capital, and RiverPark Ventures. With this funding, Solace will significantly expand its national network of more than 2,000 experienced advocates serving Medicare and Medicare Advantage members, while accelerating investment in its platform and clinical research. The company will also deepen partnerships with payers and providers to embed advocacy earlier in the care journey where outcomes are most at risk.
The Wilson Sonsini team that advised IVP on the transaction included Becki DeGraw, Madeleine Vella, Andrea Linna, Nawa Lodin, Chris Paniewski, Isabel Annino, and Daniel Chen.
For more information, please see Solace Health’s news release. Additional coverage is available on Fierce Healthcare and MedCity News.
News Articles
1.06.26
Wilson Sonsini Lawyer Andrea Linna Quoted by Inside Health Policy on State Laws Regulating AI in Mental Health Care in 2026
Wilson Sonsini partner Andrea Linna was quoted in an Inside Health Policy article titled “State Legislatures to Weigh AI Mental Health, Transparency and Sandbox Bills In 2026,” providing insight on state-level regulatory oversight of AI in mental health care. Andrea described how AI in the context of mental health remains top of mind for state legislatures “with states such as Illinois restricting how AI can be used in counseling services.”
Alerts
12.19.25
Navigating CMS’s ACCESS Model and FDA’s TEMPO Pilot: Opportunities for Digital Health Companies
Since the publication of this Alert, CMS has officially released the Request for Applications (RFA), which provides clarifications and significantly more detail on eligibility criteria, application timelines, requirements for each ACCESS Participant’s Medical Director, eligibility for inclusion in the Tools Directory, and the model’s financial structure. Interested organizations should carefully review the RFA for specific requirements that were not available at the time this Alert was published and may contact Wilson Sonsini’s Digital Health practice with any questions.
Alerts
12.16.25
Trump Administration Issues Executive Order on National AI Policy and Deregulation
On December 11, 2025, the White House issued an Executive Order (EO), “Ensuring a National Policy Framework for Artificial Intelligence,” that establishes a new federal policy on artificial intelligence (AI). The EO states that it is “the policy of the United States to sustain and enhance the United States’ global AI dominance through a minimally burdensome national policy framework for AI.” The EO asserts that leadership in AI is critical to U.S. national and economic security and dominance and that “AI companies must be free to innovate without cumbersome regulation.” To accomplish this, the EO seeks to challenge “onerous” state AI laws through various federal actions.
News Articles
12.08.25
Wilson Sonsini Lawyer Andrea Linna Quoted by WSJ on AI in Healthcare
Wilson Sonsini partner Andrea Linna was quoted in a Wall Street Journal article titled “Counsel Health Grabs $25 Million for AI-Augmented Healthcare Service,” offering insight on federal regulatory oversight of AI in healthcare. Andrea explained that whether such systems fall under U.S. Food and Drug Administration regulation generally depends on “the intended use of the AI, whether a provider is in the loop and if the provider can make independent, informed clinical decisions and independently review the basis for the AI’s recommendations.”
Client Highlights
12.03.25
Wilson Sonsini Advises Serent Capital on Recapitalization and Exit from Axiom Medical
On December 3, 2025, Serent Capital, a growth-focused private equity firm, announced the successful recapitalization of Axiom Medical, a leading provider of technology-enabled workplace injury management and employee health solutions. After a seven-year partnership with Serent Capital, Axiom Medical has received a strategic growth investment from NMS Capital to support its next phase of expansion. Wilson Sonsini Goodrich & Rosati advised Serent Capital on the transaction.
The Wilson Sonsini team that advised Serent Capital on the transaction included:
M&A
Rob Ishii
Catherine Riley Tzipori
David Adler
Elia Perez Villamarin
Yifeng Li
Eric Conner
Tax
Jonathan Zhu
Derek Wallace
Han Shen
Antitrust and Competition
Ben Labow
Kimberley Biagioli
Julio Albornoz
Technology Transactions
Barath Chari
Morgan Kasenchak
Brittany Von Rueden
Stephanie Stark
Employee Benefits and Compensation
Sriram Krishnamurthy
Matthew Norgard
Madeleine Boshart
Jason Chan
Laura Yun
Employment
Nedim Novakovic
Data, Privacy, and Cybersecurity
Matt Staples
Daniel Chen
Chany Kim
Regulatory
Jodi Daniel
Andrea Linna
Nawa Lodin
For more information, please see Serent’s news release.
The Wilson Sonsini team that advised Serent Capital on the transaction included:
M&A
Rob Ishii
Catherine Riley Tzipori
David Adler
Elia Perez Villamarin
Yifeng Li
Eric Conner
Tax
Jonathan Zhu
Derek Wallace
Han Shen
Antitrust and Competition
Ben Labow
Kimberley Biagioli
Julio Albornoz
Technology Transactions
Barath Chari
Morgan Kasenchak
Brittany Von Rueden
Stephanie Stark
Employee Benefits and Compensation
Sriram Krishnamurthy
Matthew Norgard
Madeleine Boshart
Jason Chan
Laura Yun
Employment
Nedim Novakovic
Data, Privacy, and Cybersecurity
Matt Staples
Daniel Chen
Chany Kim
Regulatory
Jodi Daniel
Andrea Linna
Nawa Lodin
For more information, please see Serent’s news release.
Client Advisories
8.19.25
Offering Equity to Physicians in an MSO/PC Structure: Key Fraud and Abuse Compliance Considerations
Offering equity in MSOs to physicians can be permissible but must be structured to comply with both federal and state laws. Failure to comply with applicable fraud and abuse laws may result in civil and/or criminal penalties, repayment obligations, and exclusion from federal healthcare programs.